Corcept Therapeutics Incorporated

NasdaqCM:CORT Stock Report

Market Cap: US$5.5b

Corcept Therapeutics Past Earnings Performance

Past criteria checks 6/6

Corcept Therapeutics has been growing earnings at an average annual rate of 3.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 12.6% per year. Corcept Therapeutics's return on equity is 22.2%, and it has net margins of 22.4%.

Key information

3.3%

Earnings growth rate

6.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate12.6%
Return on equity22.2%
Net Margin22.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump

Dec 04
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

Revenue & Expenses Breakdown

How Corcept Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:CORT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24629140244231
30 Jun 24570125216217
31 Mar 24524117192202
31 Dec 23482105184184
30 Sep 2345091179166
30 Jun 2342894169154
31 Mar 2341494164144
31 Dec 22402101153131
30 Sep 22398117143123
30 Jun 22392113138118
31 Mar 22380112130113
31 Dec 21366113122114
30 Sep 21353106116114
30 Jun 2134398112119
31 Mar 2134099107118
31 Dec 20354106105115
30 Sep 20356109107111
30 Jun 20351114104100
31 Mar 2033510610495
31 Dec 193069410089
30 Sep 19285879583
30 Jun 19268789280
31 Mar 19258768778
31 Dec 18251758175
30 Sep 182381527770
30 Jun 182161487263
31 Mar 181891426650
31 Dec 171591296240
30 Sep 17130355733
30 Jun 17109245229
31 Mar 1793135026
31 Dec 168184524
30 Sep 167254221
30 Jun 166414118
31 Mar 1656-23816
31 Dec 1550-63715
30 Sep 1544-113615
30 Jun 1538-173615
31 Mar 1532-223515
31 Dec 1427-313518
30 Sep 1422-393421
30 Jun 1417-443223
31 Mar 1413-483323
31 Dec 1310-463120

Quality Earnings: CORT has high quality earnings.

Growing Profit Margin: CORT's current net profit margins (22.4%) are higher than last year (20.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CORT's earnings have grown by 3.3% per year over the past 5 years.

Accelerating Growth: CORT's earnings growth over the past year (54.6%) exceeds its 5-year average (3.3% per year).

Earnings vs Industry: CORT earnings growth over the past year (54.6%) exceeded the Pharmaceuticals industry 54.6%.

Return on Equity

High ROE: CORT's Return on Equity (22.2%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 06:20
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Corcept Therapeutics Incorporated is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
David BuckB. Riley Securities, Inc.
Edward NashCanaccord Genuity